Fuzhou Changfuxing Biopharmaceutical Technology

Changfuxing Biopharmaceutical is a clinical-stage biotechnology company based in Fuzhou, China, specializing in the development of innovative small molecule therapeutics for metabolic diseases. The company's lead program, CFX-101, is a potent and selective URAT1 inhibitor currently being evaluated in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Changfuxing focuses on addressing unmet medical needs in the metabolic space by leveraging its internal R&D capabilities to design drugs with improved safety and efficacy profiles compared to existing standards of care. The company maintains a strong focus on the Chinese domestic market while exploring global development opportunities for its pipeline.